Session date: 
Friday, April 20, 2018 - 8:00am to 9:00am
Location: 
Froedtert Hospital
9200 W Wisconsin Avenue
Dean Roe Auditorium
Milwaukee, WI 53226
United States
  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 APA
    APA credit.
  • 1.00 Hours of Participation
    Hours of Participation credit.

Please login or register to take this course.
Program Description: 

Weekly grand rounds as a forum for clinical and basic research updates in neurology with respect to diagnosis and management of neurological disorders and advances in neuroscience.  General areas of focus will include among others the following:  neuromuscular, epilepsy, sleep, movement disorders, stroke and vascular disorders, neurodegenertive, dementia and memory disorders, headaches and cranial neuralgias, autonomic disorders, and general neurologic conditions.

ACCME Accreditation Statement
The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 
AMA Designation of Credit Statement
The Medical College of Wisconsin designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Hours of Participation for Allied Health Professionals
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.
 

Psychology CE Credit Statement:
The Medical College of Wisconsin is approved by the American Psychological Association to sponsor continuing education for psychologists.  The Medical College of Wisconsin maintains responsibility for this program and its content.
This activity contains content or processes that may be potentially stressful.

Target audience: 

Physicians
Allied Health Care Professionals
Psychologists

Learning objectives: 

Gabriel Bonnell, MD

1. Explain the history of Synthetic Cannabinoids”

2. Compare how Synthetic cannabinoids differ from "traditional" cannabis use

3. Assess the potential neurologic complications of Synthetic cannabinoid use

 David Shirilla. DO

  1. Discuss the AAN/AANEM's recommendations for screening labs in Distal Symmeric neuropathy
  2. Identify characteristics of patients presentations of sensory changes necessiating more intensive work-up
  3. Evauation of the role of the Oral Glucose Tolerance test in a neurology practice
  4. Discuss utility of targeted genetic testing in patient's with suspected hereditary neuropathy
  5. Review monoclonal gammopathies and overlap with neuropathy, as well as indications for and baseline interpretation of SPEP
  6. Examine the additional dianostic data provided )or not provided) with electrodiagnositc (EDX) testing in neuropathy
Faculty & credentials: 

Presenter:  

Gabriel Bonnell, MD- PGY-IV graduating resident

David Shirilla, DO- PGY-IV graduating resident 

Activity Director: Derrick Shumate, DO

Planning Committee:
Ann Helms, MD
Chad Carlson, MD
David Sabsevitz, PhD

All persons in control of content have NO relevant financial relationships to disclose.

CME Coordinator Contact Information

Name: 
Gail Balistreri
Phone number: 
+1 (414) 805-5204